Bristol Myers Secures $1B Deal with Tubulis to Advance Cancer Treatments
April 21, 2023
Trending News 🌧️
BRISTOL-MYERS ($NYSE:BMY): Bristol Myers Squibb, a leading biopharmaceutical company, recently made headlines when it secured a licensing agreement worth up to $1 billion with Tubulis, a biotechnology company. This deal will allow Bristol Myers to advance its cancer treatments through the development of Tubulis’s novel drug candidates. The company is the leader in immuno-oncology, working diligently to bring the latest treatments to patients. The recently-signed agreement between Bristol Myers Squibb and Tubulis is an exciting opportunity for both companies.
The deal will allow Bristol Myers to access Tubulis’s novel drug candidates, which could potentially be used to develop cancer medications. Furthermore, Bristol Myers could potentially receive up to $1 billion in the long term. This agreement is yet another testament to the company’s commitment to developing groundbreaking treatments and advancing cancer care.
Market Price
On Thursday, Bristol Myers Squibb (BMS) announced that they had secured a deal with Tubulis to invest $1 billion in cancer treatments over the next several years. In reaction to the news, BMS stock opened at 69.7 and closed at 69.5, down by 0.5% from their prior closing price of 69.9. The deal comes as a major investment in cancer treatments and is expected to have a positive impact in the field of oncology.
With this announcement, BMS aims to continue its commitment to advancing cancer treatments and providing solutions to those affected by the disease. This is yet another move from BMS to demonstrate its dedication to improving the lives of individuals with cancer. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bristol-myers Squibb. More…
| Total Revenues | Net Income | Net Margin |
| 46.16k | 6.33k | 16.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bristol-myers Squibb. More…
| Operations | Investing | Financing |
| 13.07k | -1.06k | -16.96k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bristol-myers Squibb. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 96.82k | 65.7k | 14.97 |
Key Ratios Snapshot
Some of the financial key ratios for Bristol-myers Squibb are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.9% | 15.5% | 19.4% |
| FCF Margin | ROE | ROA |
| 25.9% | 17.5% | 5.8% |
Analysis
At GoodWhale, we conducted an analysis of BRISTOL-MYERS SQUIBB‘s wellbeing. Our Risk Rating reveals that the company is a high risk investment in terms of financial and business aspects. Upon further inspection, our team has picked up three risk warnings that were detected on their income sheet, balance sheet and non-financial accounts. We invite you to register with us to get a better insight into the risk factors associated with this particular company. At GoodWhale, we strive to provide investors with the most accurate and up-to-date information on companies. We understand that investing is a daunting task and we are here to help you make informed decisions. So, join us today and find out more about BRISTOL-MYERS SQUIBB’s wellbeing. More…
Peers
The company was founded in 1887 and is headquartered in New York City. The company’s products are sold in over 100 countries. Bristol-Myers Squibb Co’s competitors include Merck & Co Inc, Amgen Inc, Eli Lilly and Co.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co Inc is a global health care company that offers a wide range of products and services to customers in more than 140 countries. The company has a market cap of 236.25B as of 2022 and a Return on Equity of 28.84%. Merck & Co Inc is a diversified company that operates in four main business segments: Pharmaceuticals, Vaccines, Animal Health, and Consumer Care. The company’s products include prescription and over-the-counter medicines, vaccines, biologic therapies, and consumer and animal health products. Merck & Co Inc is one of the world’s largest pharmaceutical companies and is a leading provider of health care products and services.
– Amgen Inc ($NASDAQ:AMGN)
Amgen Inc is a large biotechnology company with a market cap of 132.76B as of 2022. The company has a strong return on equity of 460.37%. The company focuses on developing and delivering therapies for serious illnesses.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 312.88B as of 2022. Its return on equity is 45.88%. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products. It offers products in the areas of endocrinology, diabetes, oncology, immunology, neuroscience, and erectile dysfunction.
Summary
Bristol-Myers Squibb (BMS) recently announced a $1 billion licensing agreement with Tubulis to develop cancer treatments. This is a major investment for BMS, as the company looks to expand its portfolio of oncology medicines. BMS expects the agreement to enhance its pipeline of cancer treatments and increase the value of its portfolio through potential new treatments.
Additionally, BMS believes that its R&D capabilities and the expertise of Tubulis will play a major role in the success of the collaboration. Investors should keep an eye on the development of this partnership as it could have a positive impact on BMS’s market performance going forward.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
